This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
Here's Why Investors Should Retain Phibro (PAHC) For Now
by Zacks Equity Research
Investors are optimistic about Phibro's (PAHC) major animal health products and robust vaccine sales.
LabCorp (LH) Debuts NfL Test for Neuronal Damage Diagnosis
by Zacks Equity Research
LabCorp's (LH) widely accessible NfL blood test presents direct evidence of neuronal injury resulting from brain injury or diseases like Alzheimer's, among others.
Here's Why You Should Buy DENTSPLY SIRONA (XRAY) Stock Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.
Fresenius (FMS) Faces Fraud Accusation From US Government
by Zacks Equity Research
The Department of Justice of the U.S. government files a civil complaint against Fresenius (FMS), accusing it of defrauding Medicare and other healthcare programs by billing for unnecessary procedures.
Zacks.com featured highlights include AMN Healthcare Services, Otter Tail, Encore Capital Group and Cboe Global Markets
by Zacks Equity Research
AMN Healthcare Services, Otter Tail, Encore Capital Group and Cboe Global Markets are part of zacks Screen of the week article.
This Medical Supplier Is Pushing All-Time Highs
by Derek Lewis
McKesson shares have been scorching-hot year-to-date, increasing by more than 30% in value and extensively outperforming both its Zacks Sector and the S&P 500.
AMN Healthcare Services (AMN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed the most recent trading day at $110.24, moving -1.09% from the previous trading session.
Here's Why You Should Retain Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) strong end market growth and noteworthy acquisitions.
3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.
CVS Health (CVS) Pharmacy Claims Volume Grows, Margin Woes Stay
by Zacks Equity Research
CVS Health's (CVS) investments in constructing affordable housing units in Denver, Fresno, Nashville and San Antonio seem encouraging.
AngioDynamics (ANGO) Q4 Earnings in Line, Revenues Beat Mark
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in Med Tech and Med Device businesses, as well as in its GBUs, in fourth-quarter fiscal 2022.
Haemonetics (HAE) Hospital Arm Thrives, Gross Margin Rises
by Zacks Equity Research
Strong procedure recovery in the hospital business, the resilience of blood donors in blood centers and rollouts of Persona technology and NexSys aid Haemonetics (HAE).
Here's Why You Should Add Glaukos (GKOS) to Your Portfolio
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
4 Stocks Trading Near 52-Week High That Can Scale Higher
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run lately. Stocks like AMN, OTTR, ECPG and CBOE that are seeing price strength have a high chance of carrying the momentum forward.
Zacks.com featured highlights include JSanderson Farms, Otter Tail, J&J Snack Foods and AMN Healthcare
by Zacks Equity Research
JSanderson Farms, Otter Tail, J&J Snack Foods and AMN Healthcare are part of Screen of the Week article.
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why You Should Retain Walgreens Boots (WBA) For Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA), given its better-than-expected earnings and strategic alliances.
Cardinal Health's (CAH) New Buyout to Boost Medication Adherence
by Zacks Equity Research
Cardinal Health's (CAH) latest acquisition is expected to significantly improve patients' health outcomes with improved medication adherence and increased satisfaction.
Buy These 4 Low-Beta Stocks to Sail Through a Volatile Market
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Sanderson (SAFM), Otter Tail (OTTR), J&J Snack Foods (JJSF) and AMN Healthcare (AMN) are well poised to gain.
Here's Why You Should Hold on to CONMED (CNMD) Stock Now
by Zacks Equity Research
CONMED (CNMD) continues to gain momentum from a solid product portfolio and a strong General Surgery business. However, data security issues linger.
Factors that Make Acadia Healthcare (ACHC) an Attractive Bet Now
by Zacks Equity Research
Solid demand for behavioral healthcare services, growth-related efforts in the form of JVs, declining debt burden and sufficient cash-generating abilities continue to benefit Acadia Healthcare (ACHC).
Henry Schein's (HSIC) New Buyout Expands Its Switzerland Base
by Zacks Equity Research
Henry Schein (HSIC) serves the Swiss dental implant market through its Basel-based division, Camlog Biotechnologies GmbH, since 2004.
Merit Medical's (MMSI) New Launch to Improve Patient Outcome
by Zacks Equity Research
Merit Medical's (MMSI) latest launch will likely aid in precisely targeting affected tissues, thereby resulting in more successful surgeries and improved patient outcomes.
Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.